Table 1: Baseline characteristics.

CharacteristicImatinib + BSC
( )
BSC alone
P value

Age (years)
 Median (range)54.5 (48–7)62.5 (41–73)
Change in PS*
 No change124
Primary site of cancer
 Small intestine77
Metastatic sites
Duration of initial treatment with imatinib, months
 Median (range)41 (20–79)19.5 (1–49)
Best response to initial treatment with imatinib
Reason for cessation of initial imatinib treatment
Duration of sunitinib therapy, months
 Median (range)7.5 (3–17)6 (1–34)

BSC: best supportive care; ECOG PS: Eastern Cooperative Oncology Group Performance Status; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: not evaluable.
*Compared with presunitinib status.
Fisher’s exact test.